Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCryst Pharmaceuticals has reported positive Phase 2b trial results of an enzyme inhibitor - BCX4208 to treat gout.
Subscribe to our email newsletter
The double-blind, dose-response, randomized study enrolled 279 patients to five study arms BCX4208 at doses of 5 mg, 10 mg, 20 mg, 40 mg and placebo, administered once-daily for 12-weeks.
Allopurinol 300 mg once-daily was administered in all study arms.
The primary endpoint of the study, the proportion of patients with sUA <6 mg/dL at day 85, was
acheived.
BCX4208 was superior to allopurinol plus placebo (p=0.009 overall), when added to allopurinol 300 mg.
BioCryst Pharmaceuticals senior vice president & CMO William Sheridan said they expect to report 6-month results from the ongoing extension study in early 2012, which will provide additional insight into BCX4208’s safety and efficacy profile.
"We are on track to conclude this Phase 2 program during the first half of next year and we look forward to discussing the results in more detail with regulatory authorities and potential partners," Sheridan said.